gene-silencing therapies to treat neurodegenerative diseases, including diseases of Cognitive Impairment (e.g. Alzheimer’s disease, Parkinson’s disease) as well as Huntington’s disease.

Ophidion platform technology is amenable to delivering multiple classes of drugs, including small molecules and macromolecules (gene therapeutics, siRNA’s, antibodies, peptides, and other macromolecules). It also has an advanced program that is positioned to start pivotal clinical trials to treat anxiety-related disorders, together with a patented companion biomarker diagnostic to select the appropriate patient population.